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A sensitive new method for the quantitation of 5-bromodeoxyuridine (BrdUrd) incorporated 
into DNA by CC/MS analysis of enzymatically released Thy and bromouracil (BrUra) is 
presented. The hydrolysis procedure was characterized and found to give uniform results when 
sample size was 1- 10 rug DNA and incubation time for DNA digestion was between 40 min and 
16 h. Samples of DNA containing ‘H-labeled BrdUrd were analyzed in parallel by the GC/MS 
technique and by specific radioactivity and buoyant density measurements, in order to compare 
the three methods. The GC/MS procedure gave values for percentage replacement of Thy by 
BrUra which were higher than those obtained by specific activity and lower than those obtained 
by buoyant density. This GC/MS method can detect 1% replacement in a I-pg DNA sample, 
equivalent to approximately 10s cells or 0.1 mg tissue, and will permit sensitive and quantitative 
analysis of the presence of this chemotherapeutic agent/radiosensitizer in cellular DNA from 
biopsy samples of normal or tUmOr tissue. 0 1987 Academic Press, Inc. 
KEY WORDS: gas chromatography-mass spectrometry; ultracentrifugation; DNA: purines 
and pyrimidines; cancer chemotherapy. 
The thymidine analog 5-bromodeoxyuri- 
dine (BrdUrd)4 has long been recognized for 
its capacity to become incorporated into 
DNA and, as one result of such incorpora- 
tion, to sensitize cells to radiation ( 1). Several 
reports have shown that the magnitude of 
this radiosensitization is proportional to the 
extent to which BrdUrd replaces dThd in 
DNA (2-5). In most such studies BrdUrd in- 
corporation has been calculated on the basis 
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of changes in buoyant density of DNA ex- 
tracted from treated cells by the use of CsCl 
gradient sedimentation. There are a number 
of serious difficulties associated with this 
procedure, however. For example, relatively 
few samples can be processed at a time (de- 
pending on the number of available rotors 
and centrifuges); the formation, fractiona- 
tion, and analysis of the gradients are time 
consuming; and such analyses require either 
large quantities of DNA (enough to be de- 
tected by uv absorbance) or radiolabeled 
DNA, which might not be easily obtained 
from clinical tissue specimens. Since there 
has recently been a resurgence of interest in 
the clinical use of BrdUrd as a radiosensitizer 
(6) we felt that a more convenient and direct 
means of measuring BrdUrd incorporation 
would be a useful tool. In this paper we de- 
scribe a technique in which DNA is isolated 
from cells and enzymatically hydrolyzed to 
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yield thymine and bromouracil, which are 
then quantitated by GC/MS analysis. A 
comparison of results obtained by use of this 
method versus those found by employing 
CsCl gradient analysis and specific radioac- 
tivity calculations is presented, showing that 
the GC/MS technique yields values for the 
extent of replacement of dThd by BrdUrd 
which are intermediate between the other 
two techniques. 
MATERIALS AND METHODS 
Ceil growth, drug treatment, and DNA 
preparation. Vl9 cells were grown as mono- 
layers in 150-cm2 tissue culture flasks in 
CX-MEM containing 5% fetal calf serum. 
L12 10 cells were grown as suspension cul- 
tures in RPM1 1640 containing 10% horse 
serum. Media and sera were purchased from 
GIBCO. BrdUrd solutions were freshly pre- 
pared for each experiment by dissolving 
BrdUrd powder (Sigma) in 0.1 M NaOH and 
diluting a small aliquot of this filter-sterilized 
stock solution into the medium. Drug con- 
centration in the stock solution was checked 
by uv absorbance. Radioactive BrdUrd 
solutions were made by combining stock 
[‘H]BrdUrd (6-‘H, 16 Ci/mmol, Moravek 
Biochem.) with unlabeled BrdUrd to achieve 
a final specific activity of 188 mCi/mmol. 
Radiolabeled dThd (2-14C, 56 mCi/mmol) 
was also purchased from Moravek. After 
drug treatment cells were harvested by tryp- 
sinization and pelleted, the medium was re- 
moved, and 1 .O ml of lysis buffer was added 
(10 ITIM Tris-HCl, pH 8.0, 1 mM EDTA, 
0.6% SDS). Lysates were sheared with an 18- 
gauge needle and then treated with protein- 
ase K (Sigma), 50 Kg/ml, for 2 h at 37°C. 
This material was then extracted twice with 
chloroform and precipitated with 2 vol of 
ice-cold 95% ethanol and a final concentra- 
tion of 0. I M NaCl and kept at -20°C. After 
ethanol precipitation the samples were al- 
lowed to warm to room temperature and the 
DNA was pelleted, air-dried, and dissolved 
in at least 1 .O ml of TE ( 10 mM Tris-HCl, 
pH 8.0; 1 IIIM EDTA). Samples were then 
treated with DNase-free RNase at a concen- 
tration of 0.02 mg/ml for 2 h at 37”C, chlo- 
roform extracted once, and ethanol precipi- 
tated as before. 
DNA hydrolysis. Aliquots of DNA solu- 
tions were diluted to a final volume of 250 ~1 
with TM (10 mM Tris-HCl, pH 8.0; 10 mM 
MgC12) and 50 ~1 of “enzyme mix.” Enzyme 
mix contains 2 mg/ml DNase I, 4 mg/ml 
phosphodiesterase, 70 units/ml alkaiine 
phosphatase, and 25 units/ml thymidine 
phosphorylase in TM (pH 8.0) and is made 
fresh daily. All enzymes were supplied by 
Sigma. The hydrolysis reaction was carried 
out for 1 h (unless indicated otherwise) at 
37°C and stopped by adding 100 ~1 of satu- 
rated ammonium sulfate. Hydrolysates were 
stored at -20°C until extraction, derivatiza- 
tion, and analysis by GC/MS, as described 
previously (7). 
Determination of incorporation using CsCI 
gradients. Five milliliters of CsCl solution (at 
a starting density of 1.712 to 1.726 g/ml, 
25°C) including aliquots of both 14C-labeled 
(control) and 3H-labeled (BrdUrd) DNA was 
placed in a Beckman Ultra-Clear centrifuge 
tube. Each tube contained no more than 2 pg 
of DNA. An overlay of 6 ml of light mineral 
oil was added, and the tubes were capped and 
then centrifuged in a Beckman LS-70M Ul- 
tracentrifuge for 45 h at 36000 rpm at 25°C 
in a type 70.1 Ti rotor. After centrifugation 
the tubes were individually pierced and con- 
secutive 170-~1 fractions were removed from 
the bottom using an ISCO Model 184 frac- 
tionator. For each tube the density of every 
odd-numbered fraction was determined by 
refractometry. To the remaining portion of 
each fraction 2 ml of distilled water and 15 
ml of Safety-Solve were added and the radio- 
activity was counted in each fraction, The 
percentage of total corrected counts was 
plotted against fraction number and the den- 
sity of peaks was determined from a linear 
least-squares fit for the densities along the 
gradient. GC content of normal DNA was 
determined using the following equation: 
density = 1.66 + 0.098 GC where GC is the 
percentage of guanine plus cytosine (8). Per- 
166 MAYBAUM ET AL, 
TABLE 1 
RECOVERY OF [3H]BrUra FROM DNA CONTAINING [3H]BrdUrd” 
BrdUrd % Recovered 
concn. cpm cm cpm recovered cpm in nmol dThd % Replacement of 
(PM) injected recovered as BrUra BrUra peak recovered Thy by BrUra 
0.1 I 822 870 827 95.1 0.48 1.4 
0.11 986 773 730 94.4 0.44 1.4 
0.33 4444 3636 3490 95.6 0.53 5.2 
0.33 4304 3723 3566 95.8 0.55 5.1 
0.33 4364 3612 3457 95.7 0.56 4.9 
1.0 9786 7002 6707 95.8 0.30 15.7 
1.0 8002 7136 6858 96.1 0.44 11.5 
’ DNA was extracted from V79 cells grown in the indicated concentration of [3H]BrdUrd (sp act 188 mCi/mmol) 
for 48 h and then hydrolyzed as described in the text. The hydrolysate was injected onto a reverse-phase HPLC 
column and I. 1 -ml fractions were collected, mixed with an aqueous-compatible scintillation cocktail, and assayed 
for ‘H by liquid scintillation counting. Thymidine content of each sample was determined by use of an external 
calibration curve and extent of Thy replacement by BrUra was calculated on the basis of ‘H recovered as BrUra and 
recovered dThd, using an experimentally determined ‘H counting efficiency of 29%. 
centage BrdUrd incorporation was calcu- 
lated as in Ref. (9), assuming that BrdUrd 
incorporation causes no significant change in 
the partial specific volume of DNA. 
HPLC analysis. The HPLC system con- 
sisted of an Altex 110 pump, a Rheodyne 
7 120 injector with a 200~~1 loop, and a 
Waters 440 uv absorbance detector fixed at 
280 nm. DNA hydrolysates were extracted 
with chloroform before being injected onto a 
Regis 4.6 X 250-mm, 5-pm ODS column, 
using a mobile phase containing 10 mM 
NaOAc, pH 5.0, 5% MeOH at a flow rate of 
1.1 ml/min. Under these conditions Thy, 
BrUra, dThd, and BrdUrd eluted at 8.5, 9.5, 
21, and 29 min, respectively. 
RESULTS AND DISCUSSION 
Characterization of DNA Hydrolysis 
In order to determine the efficiency of lib- 
eration of thymine and bromouracil from 
DNA we used HPLC to analyze the hydroly- 
sate of DNA containing either [14C]dThd or 
[3H]BrdUrd. Table 1 shows that when the 
incorporated radioactivity was [3H]BrdUrd 
85% of injected radioactivity was recovered 
in the collected fractions. and at least 95% of 
the cpm coeluted with bromouracil, with the 
remaining cpm eluting at the same time as 
thymine. The identity of this minor compo- 
nent was not investigated further. In hy- 
drolysates of DNA samples containing 
[ 14C]dThd all detectable radioactivity co- 
eluted with thymine, accounting for 85.5 
rt 3.2% (SD, N = 3) of injected cpm. We 
conclude from these data that the hydrolysis 
conditions used here release both thymine 
and bromouracil from DNA with high effi- 
ciency and with little or no alteration of their 
chemical identities. 
The time course of hydrolysis under these 
conditions is quite rapid, as shown by the 
data in Table 2. Since 10 /lg L1210 DNA 
would be expected to contain approximately 
9 nmol of Thy + BrUra (assuming 40% G 
+ C content and an average of 330 Da per 
monophosphate) the observed amounts of 
these two bases indicate that hydrolysis is 
complete after 40 min of incubation. In 
other experiments we hydrolyzed replicate 
samples of 1 or 5 pg of the same DNA prepa- 
ration for 16 h and observed values for re- 
placement of Thy by BrUra of 32.7 -t 1.6 and 
34.7 k 0.5%, respectively (&SD, N = 4). The 
mean of all of the values in Table 2 is 34.2 
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TABLE 2 
TIME COURSE OF DNA HYDROLYSIS 
Incubation time nmol BrUra nmol Thy Total nmol % Replacement of 
(min) recovered recovered recovered Thy by BrUra 
20 2.41 4.60 7.01 34.4 
2.15 5.33 8.08 34.0 
40 2.95 5.60 8.55 34.5 
3.28 6.20 9.48 34.6 
60 2.92 5.71 8.63 33.8 
3.00 5.90 8.90 33.1 
’ Ten-microgram samples of DNA isolated from L12 10 cells grown in 10 pM BrdUrd for 48 h were hydrolyzed for 
varying periods of time at 37°C using the enzyme mixture described under Materials and Methods, after which the 
hydrolysates were assayed for Thy and BrUra by the CC/MS method. 
f 0.4 (SD). These data indicate that the ex- 
tent ofBrdUrd incorporation obtained with the 
GC/MS method is independent of sample 
size (in the range of l-10 fig) and hydrolysis 
time (between 20 min and 16 h). 
In preliminary experiments we noted that 
the lot of thymidine phosphorylase on hand 
contained a small amount of Thy (2.9 ng 
(0.02 nmo1)/25 units enzyme) which could 
significantly change the apparent extent of 
BrdUrd incorporation in very small samples 
(e.g., co.05 gg). All data reported here 
are corrected for the presence of this exoge- 
nous Thy. 
Comparison with Other Methods 
In previous studies the most common 
methods for determining the extent of 
BrdUrd incorporation have been CsCl gra- 
dient sedimentation (10,ll) or specific activ- 
ity calculation following incorporation of ra- 
diolabeled BrdUrd (4,12). In order to com- 
pare these techniques with the one presented 
here we prepared DNA samples from V79 
cells exposed to various concentrations of 
[3H]BrdUrd and then determined the extent 
of BrdUrd substitution by each of the three 
methods. Values for incorporation based on 
specific activity are given in Table 1. Results 
found by the GC/MS method are shown in 
Table 3, and data derived from CsCl gra- 
dients are given in Table 4. A summary of all 
of these data appears in Fig. 1. 
As expected, each method reveals an ap- 
parent increase in incorporation with in- 
creasing drug concentration. We also observe 
consistent differences among the techniques, 
as within each group the value obtained by 
GC/MS is lower than those obtained by CsCl 
gradients and higher than those seen using 
specific activity. Since each of these methods 
is prone to experimental error, none can be 
considered to be a standard. It is therefore 
difficult to make an assessment of the abso- 
lute accuracy of any of them. However, an 
examination of the details of each method 
BrdUrd CCMC. +M) 
FIG. 1. Comparison of percentage replacement of Thy 
by BrUra, as determined by three independent methods. 
Data shown are a composite of results given in Tables I, 
3, and 4. 
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TABLE 3 
ANALYSIS OF BrdUrd INCORFQRATION BY @Z/MS” 
BrUra concn. Sample size nmol BrUra nmol Thy Total nmol % Replacement of 
(PM) w recovered recovered recovered Thv bv BrUra 
0.11 1 0.037 0.606 0.643 5.7 
0.029 0.559 0.588 4.9 
0.33 1 0.061 0.548 0.609 9.9 
0.062 0.529 0.591 10.5 
0.33 10 0.500 4.49 4.99 10.0 
0.48 1 4.23 4.71 10.2 
1.0 1 0.093 0.532 0.625 14.8 
0.104 0.570 0.674 15.4 
’ Portions of the DNA samples used to produce the data shown in Table 1 were separately hydrolyzed and analyzed 
by GC/MS as described in the text. 
and the assumptions used in calculating in- 
corporation values in each case suggests that 
the specific activity and GC/MS data may be 
more representative of actual incorporation 
than CsCl gradient data. 
Values for incorporation based on specific 
activity calculations depend on experimental 
determination of radioactivity incorporated 
as BrUra, amount of DNA analyzed (or, 
more directly, the amount of Thy in the sam- 
ple), and the specific activity of the incorpo- 
rated BrUra. Data in Table 1 show that our 
hydrolysis procedure releases both Thy and 
BrUra with the same high efficiency and that 
greater than 95% of 3H coelutes with BrUra. 
The hydrolysis procedure is therefore un- 
TABLE 4 




3H “Y % Replacement % Replacement 
Peak Mean Peak Mean Using Group Using Group 
frac. frac. frac. frac. peak frac. mean mean frac. mean 
0.11 19 19.62 23 22.8 10.0 10.5 7.7 8.5 
18 19.15 22 22.47 10.0 8.8 







11.61 16 16.99 17.9 19.2 18.7 17.1 
12.46 18 18.00 21.5 16.4 
13.09 19 18.73 18.1 16.3 
12.50 21 20.14 25.0 22.6 20.5 18.6 
11.18 19 18.15 21.9 18.5 
8.69 17 16.13 21.0 16.8 
’ One-microgram aliquots of V79 DNA containing [3H]BrdUrd (same preparations as in Tables 1 and 3) were 
combined with control DNA containing [14C]dThd and sedimented to equilibrium in CsCl gradients. Tubes were 
punctured from the bottom and fractions were collected and assayed for radioactivity by liquid scintillation counting. 
Corrections for background and spillover were based on standards prepared similarly to these samples. 
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likely to be a major source of error in either 
the specific radioactivity or the GC/MS cal- 
culations. Determination of Thy recovered 
from each HPLC injection is characterized 
by a coefficient of variation of 6.3% (data not 
shown). The radiopurity of our [3H]BrdUrd 
was determined by reverse-phase HPLC 
analysis, by coinjection of a known amount 
of that compound along with unlabeled 
BrdUrd and BrUra as carriers. All of the in- 
jected radioactivity was recovered in frac- 
tions collected for 35 min postinjection, with 
96.5% of the 3H cpm eluting with BrdUrd 
and the remaining 3.5% eluting with BrUra. 
Overall, there is no obvious source of either 
random or systematic error greater than 
those ordinarily associated with HPLC anal- 
ysis or scintillation counting. 
In examining the sources of error asso- 
ciated with the GC/MS procedure, we can 
divide this assay into two sections: (i) DNA 
hydrolysis and (ii) extraction and GC/MS 
quantitation of released bases. Since the hy- 
drolysis procedures for the GC/MS method 
and the specific activity method are identi- 
cal, this portion of the assay cannot account 
for any observed differences between the two 
techniques. We have previously character- 
ized the second half of the analytical proce- 
dure in detail and found that the coefficient 
of variation for determination of either 
BrUra or Thy is less than or equal to 
10.2% (7). 
Assessment of BrdUrd by CsCl gradient 
sedimentation is based on the assumptions 
that the change in partial specific volume of 
DNA caused by replacement of Thy by 
BrUra is negligible and that the position of 
the peak of radioactivity in a gradient con- 
taining DNA labeled with [3H]BrdUrd is rep- 
resentative of the mean density of that DNA 
sample. While we have no reason to believe 
that BrdUrd incorporation causes a major 
alteration in DNA partial specific volume, 
the skewed nature of the distribution of 
BrdUrd-associated radioactivity (as illus- 
trated in Fig. 2) makes the second assump- 
tion unlikely. Such asymmetrical distribu- 
tions have been reported previously and were 
FRACTION NUMBER 
FIG. 2. Representative data are shown from an experi- 
ment in which BrdUrd replacement was assayed by CsCl 
gradient sedimentation. In this example DNA was iso- 
lated from V79 cells grown in either 0.33 PM 
[3H]BrdUrd or [“%]dThd and sedimented as described 
in the text. The density of each odd-numbered tube was 
determined refractometrically (not shown). 
interpreted to reflect heterogeneity in the 
densities of the DNA molecules under study 
(10). For this reason we calculated the appar- 
ent extent of BrdUrd substitution based on 
DNA densities corresponding to either the 
peak or the mean of the 3H distributions in 
each gradient (Table 4). In all cases the value 
derived from the mean of the radioactivity 
A more important source of error is proba- 
bly that, when the density label and the ra- 
dioactivity label are in the same molecule, 
distribution is lower than that derived from 
density profiles of heterogeneous DNA pop- 
ulations are necessarily skewed toward 
the peak. This difference is only significant 
higher densities, as shown in Fig. 3. In this 
example a hypothetical population of DNA 
(P < 0.05) in the 0.11 I.LM group, however, 
molecules is defined in which half are hy- 
brids containing one unsubstituted strand 
and in each group the values calculated from 
and one 50% substituted strand (25% substi- 
tution overall), while in the other half all 
distribution means are still higher than re- 
strands are 50% substituted. The average per- 
centage substitution in the total population is 
sults obtained using the other two methods 
therefore 37.5%. Since the more densely la- 
beled molecules also contain twice as much 
(Fig. 1). 
radioactivity per unit DNA, they will form a 
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FIG. 3. Hypothetical gradient profiles are shown for 
DNA samples containing 25 or 50% replacement of Thy 
by [3H]BrUra, or a mixture of equal amounts of each 
type of DNA. A normal distribution was assumed for 
construction of the upper two curves. 
peak with twice the height of the less densely 
labeled molecules, even though both types 
are present in equal abundance. Estimation 
of incorporation by using the peak of ra- 
dioactivity would therefore lead to a value of 
50% in this example. Even using the mean of 
the radioactivity peak, molecules containing 
higher degrees of substitution would be dis- 
proportionately weighted and the estimated 
value would still exceed the true value of 
BrdUrd incorporation. Furthermore, pieces 
of DNA within the subject population which 
were not replicated in the presence of 
BrdUrd would be ignored and therefore con- 
tribute to a still greater overestimation of the 
average extent of BrdUrd incorporation. The 
same analysis would apply if the two sub- 
populations of DNA were each substituted 
on both strands, but to different degrees, as 
could occur if BrdUrd is significantly 
depleted from the medium during incuba- 
tion (13). 
In addition to the above-mentioned differ- 
ences in precision and accuracy, the three 
methods also possess widely varying degrees 
of sensitivity. For the GC/MS and specific 
activity techniques, the limit of detection in 
terms of percentage replacement depends on 
the size of the sample used. Assuming that 10 
pg DNA is analyzed, the lowest extent of re- 
placement detectable by GC/MS analysis 
would be about 0.1%. This figure is based on 
the minimum detectable quantity of BrUra 
being 1.3 ng, or 0.007 nmol(7). 
The sensitivity of analysis by detection of 
incorporated radiolabeled BrdUrd depends 
on the specific activity of the material ad- 
ministered. In our studies, with a specific ac- 
tivity of 188 mCi/mmol, the minimum 
amount of [3H]BrdUrd which would be de- 
tectable above background is 0.0006 nmol. 
Using 10 pg of DNA this translates to 0.0 1% 
replacement. Higher specific activities would 
give proportionally lower limits of detection 
in this system. 
The minimum level of replacement detec- 
table by the buoyant density approach is 
more difficult to determine. This parameter 
is not related to sample size, but rather to the 
precision with which differences in the gra- 
dient profiles of control and experimental 
DNA samples can be measured. Under the 
conditions used here, 0.1% replacement 
would be reflected by a change in density 
corresponding to 0.03 gradient fractions. We 
therefore estimate that the sensitivity limit of 
this method is on the order of 1% or higher. 
Approaches other than those characterized 
here are available for analysis of halopyrimi- 
dine incorporation. For example, although 
we used HPLC analysis for determination of 
only Thy content of DNA hydrolysates, such 
a procedure may also be used to measure 
incorporated BrUra. The minimum amount 
of BrUra which could be detected in such 
samples was about 20 ng (data not shown), 
equivalent to 1% replacement in a lO+g 
DNA sample. Also, a method involving 32P 
postlabeling of BrdUMP derived from DNA 
has been reported (14). This procedure is re- 
ported to require 0.3 pg of DNA, although 
the minimum detectable extent of replace- 
ment was not stated. The postlabeling 
method requires an amount of sample prepa- 
ration (DNA extraction and hydrolysis) simi- 
lar to that of the GC/MS procedure and has 
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the advantage of employing a more com- 
monly available analytical instrument, i.e., 
an HPLC. On the other hand, the run time 
per sample is approximately 100 min with 
the postlabeling technique, as compared to 
10 min in the GC/MS analysis. 
The preparation of monoclonal antibodies 
directed against incorporated BrdUrd ( 15) 
has provided the basis for a series of flow 
cytometric studies in which this reagent has 
been shown to be useful in detecting BrdUrd 
in DNA (e.g., (16)). Using this approach one 
may monitor the presence of incorporated 
BrdUrd in individual members of a complex 
population, information which is of consid- 
erable value and which is not available by 
other means. Evidence that indicates that the 
binding of such antibodies is proportional to 
the extent of BrdUrd replacement of dThd in 
DNA has been presented (17), although this 
study did not describe the absolute quantita- 
tion of such replacement. 
In addition to sensitivity, accuracy, and 
precision, other factors affect the choice of a 
method for analysis of BrdUrd incorpora- 
tion. For example, while the specific ra- 
dioactivity approach is the most sensitive of 
the three discussed here, its use in clinical 
studies would be expensive, requiring the use 
of large quantities of radiolabeled BrdUrd for 
long-term infusion studies, and would entail 
the unnecessary administration of radioac- 
tivity to the patient. Use of the GC/MS 
method would avoid these problems and 
would still permit analysis of very small tis- 
sue samples. Measurement of 1% replace- 
ment, which approximates the minimum re- 
quired for detectable sensitization (5) would 
require a I-pg DNA sample, equivalent to 
10’ cells or 0.1 mg of tissue. Such a sample 
could easily be obtained by needle biopsy. 
In summary, we have presented a new 
method for measuring the substitution of 
BrdUrd into DNA, in which incorporated 
Thy and BrUra are released by enzymatic 
hydrolysis and then quantitated by GC/MS 
analysis. The hydrolysis procedure has been 
shown to be essentially complete within 40 
min and to be adequate for processing 1- 10 
pg DNA/sample. In addition, this method 
will be modified to accommodate analysis of 
incorporated IdUrd, as well as BrdUrd, ei- 
ther individually or in the same sample. The 
relative convenience and enhanced sensitiv- 
ity of this method will permit analysis of 
halopyrimidine incorporation in multiple 
specimens containing small numbers of cells 
(approximately l-2 X 105) and should be 
especially valuable in clinical studies on ra- 
diosensitization of tumors by BrdUrd or 
IdUrd. 
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